+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

PEGylated Proteins Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896194
  • Report
  • January 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Biomatrik, Inc
  • Celares GmbH
  • Creative PEGworks
  • Iris Biotech GmbH
  • Laysan Bio, Ltd.
  • Merck Millipore
  • MORE
Market Overview

The PEGylated Proteins market studied was projected to grow with a CAGR of nearly 9.3% over the forecast period. The major factor attributing to the growth of the market increasing prevalence of chronic diseases like cancer, kidney diseases, and rheumatoid arthritis. According to the National Institutes of Health (NIH), in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth. Rising adoption of protein-based drugs over non-protein based drugs wherein pegylation increases the circulation and half-life of the proteins improving the efficacy. However, drug failure and drug recalls are the major drawbacks of market growth.

Scope of the Report

As per the scope of the report, pegylation is the process of binding or alteration of biological molecules by conjugation with polyethylene glycol is known as PEGylation. PEGylation enhances the stability and solubility of the drug and declines immunogenicity by changing the electrostatic binding, confirmation, and hydrophobicity of the molecule. This report is segmented by Product Type, by Protein Type, by End-User, and by Geography.

Key Market Trends

The colony-stimulating factors segment is expected to grow at the highest rate in the forecast period.
  • Colony-stimulating factors are substances that accelerate the production of blood cells and elevate their ability to function. They do not directly influence tumors, but though their role in stimulating blood cells, they can be beneficial in supporting a person's immune system during cancer treatment.
  • The market growth of the segment is due to the increasing incidence of cancer across the globe, and the usage of peptide treatment for cancer. According to the World Health Organization (WHO) cancer is the second prominent cause of death worldwide and is accountable for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.
  • Furthermore, expanded awareness amongst patients and healthcare professionals regarding adverse effects of chemotherapy and radiation therapy is a major factor for growing focus towards alternative therapeutics such as pegylated peptide-based drugs.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall PEGylated Proteins market, throughout the forecast period. The presence of key players, the high prevalence of chronic disease patients in the region, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In the North America region, the United States holds the largest market share, the large patient pool in the country is anticipated to stimulate the demand in this region. According to the American Cancer Society, about 606,880 Americans are expected to die of cancer in 2019, which means 1,660 deaths per day.

Competitive Landscape

The PEGylated Proteins market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Merck KGaA; Thermo Fisher Scientific, Inc.; NOF America Corporation; JenKem Technology USA, Inc., Creative PEGworks; Celares GmbH; Quanta BioDesign, Ltd.; Biomatrik, Inc; Iris Biotech GmbH; Laysan Bio, Ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biomatrik, Inc
  • Celares GmbH
  • Creative PEGworks
  • Iris Biotech GmbH
  • Laysan Bio, Ltd.
  • Merck Millipore
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High prevalence of chronic diseases
4.2.2 Increase adoption of protein treatments
4.2.3 Rise in research and development funding by key players
4.3 Market Restraints
4.3.1 Drug failures and drug recall
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 PEGylation Kits & Reagents
5.1.1.1 Monofunctional Linear PEGs
5.1.1.2 Bifunctional PEGs
5.1.2 Services
5.1.3 Others
5.2 By Protein Type
5.2.1 Colony Stimulating Factors
5.2.2 Interferons
5.2.3 Erythropoietin
5.2.4 Others
5.3 By End-User
5.3.1 Pharmaceutical & Biotechnology Companies
5.3.2 Contract Research Organisations
5.3.3 Academic Research Institutes
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck Millipore
6.1.2 Thermo Fisher Scientific, Inc.
6.1.3 NOF America Corporation
6.1.4 JenKem Technology USA, Inc.
6.1.5 Creative PEGworks
6.1.6 Celares GmbH
6.1.7 Quanta BioDesign, Ltd.
6.1.8 Biomatrik, Inc
6.1.9 Iris Biotech GmbH
6.1.10 Laysan Bio, Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck Millipore
  • Thermo Fisher Scientific, Inc.
  • NOF America Corporation
  • JenKem Technology USA, Inc.
  • Creative PEGworks
  • Celares GmbH
  • Quanta BioDesign, Ltd.
  • Biomatrik, Inc
  • Iris Biotech GmbH
  • Laysan Bio, Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll